PharmaTher Announces Positive Results from Study of KETABET™ for Depression Post published:June 7, 2022 Post category:Press Release
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Post published:June 6, 2022 Post category:Press Release
Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea Post published:June 3, 2022 Post category:Press Release
Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022 Post published:June 3, 2022 Post category:Press Release
PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds Post published:June 2, 2022 Post category:Press Release
Mindmed Announces Voting Results for Annual General and Special Meeting Post published:June 1, 2022 Post category:Press Release
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome Post published:May 22, 2022 Post category:Press Release
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting Post published:May 22, 2022 Post category:Press Release
CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research Post published:May 19, 2022 Post category:Press Release